Last Updated: July 16, 2026

Claims for Patent: 8,529,908

✉ Email this page to a colleague

Summary for Patent: 8,529,908

Title:	Meningococcal conjugate vaccination
Abstract:	Conjugated meningococcal capsular saccharides will be introduced into immunization schedules in the near future, but the phenomenon of “carrier suppression” must first be addressed, particularly where multiple conjugates are to be used. In the invention, tetanus toxoid is used as the carrier protein, even where multiple meningococcal conjugates are administered at the same time and where a patient has previously been exposed to the carrier protein, either in the form of a previous immunogen (e.g. in a DTP vaccine) or as a previous carrier protein (e.g. in a Hib or pneumococcal conjugate vaccine). The invention provides a method for immunizing a patient, comprising administering multiple conjugates of meningococcal capsular saccharides, wherein each conjugate comprises a tetanus toxoid carrier protein, and the capsular saccharide, and wherein the patient has been pre-immunized with a tetanus toxoid.
Inventor(s):	Cameron John Marshall
Assignee:	GlaxoSmithKline Biologicals SA
Application Number:	US11/795,229

Details for Patent 8,529,908

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Glaxosmithkline Biologicals	MENVEO	meningococcal (groups a, c, y, and w-135) oligosaccharide diphtheria crm197 conjugate vaccine	Injection	125300	February 19, 2010	⤷ Start Trial	2026-01-13
Glaxosmithkline Biologicals	MENVEO	meningococcal (groups a, c, y, and w-135) oligosaccharide diphtheria crm197 conjugate vaccine	Injection	125300	October 14, 2022	⤷ Start Trial	2026-01-13
Glaxosmithkline Biologicals	HIBERIX	haemophilus b conjugate vaccine (tetanus toxoid conjugate)	Injection	125347	August 19, 2009	⤷ Start Trial	2026-01-13
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

International Patent Family for US Patent 8,529,908

Subscribe to access the full database, or Start Trial
Country	Patent Number	Estimated Expiration
World Intellectual Property Organization (WIPO)	2006075170	⤷ Start Trial
World Intellectual Property Organization (WIPO)	2005105140	⤷ Start Trial
United States of America	9402915	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.